Inpegsomatropin Injection (Pegpesen®)
Growth Hormone Deficiency
ApprovedApproved in China (May 2024)
Key Facts
Indication
Growth Hormone Deficiency
Phase
Approved
Status
Approved in China (May 2024)
Company
About Amoytop Biotech
A Chinese biopharma company developing and commercializing long-acting recombinant protein drugs for hepatitis, oncology, and immunotherapy.
View full company profileTherapeutic Areas
Other Growth Hormone Deficiency Drugs
| Drug | Company | Phase |
|---|---|---|
| Human Growth Hormone Biosimilar | USV Biologics Division | Phase 2 |
| BBT-031 | Bolder Biotechnology | Preclinical |
| MOD‑4023 (hGH‑CTP) | Opko Biologis | Phase 3 |